This panel features three different companies that are looking to advance innovations in rare diseases or what are often designated by the FDA is orphan drugs. We have a diverse panel of participants that can hopefully each provide their own unique perspective on the topic. Panelists include executives from Aytu BioPharma, Inc., Acasti Pharma, and Jaguar Health, Inc.

Before we sort of turn this over to the panel, I wanted to provide a little bit of background to help the conversation here. Over the decades, there’s been tremendous scientific developments on many medical products and therapeutic advances for patients. But in the late 1970s, it was becoming clear that many citizens were being left out of many of these advances. One of the key reasons for this neglect was the small size of some of the patient populations. The relatively limited prevalence of particular diseases acted as a barrier for commercial investment and the research and development required to show evidence of safety and efficacy of treatments.

This KOL Panel was recorded during our Lytham Partners Fall 2022 Investor Conference.